Together, these data show that low doses (2.5 nM) of KPT-335 and KPT-350 moderately improve neuronal survival in models of ALS and FTD involving the expression of WT but not mutant TDP43. This evidence concerns the gene TARDBP and amyotrophic lateral sclerosis.